New gel scaffold aims to improve healing after skin cancer removal

NCT ID NCT06600152

Completed Disease control Sponsor: Tempo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new gel-like wound dressing called MAP Wound Matrix (TT101) in 40 adults who had skin cancer removed with Mohs surgery. The dressing was applied right after surgery to see if it was safe and helped wounds heal compared to a standard hydrocolloid bandage. The main goal was to check for serious side effects like infections or slow healing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAP Wound Matrix (a gel-like scaffold applied to the wound)
What this could lead to: If it works, this could offer a new option to help wounds heal better after skin cancer surgery, potentially reducing complications.
What could go wrong: This is a small, early safety study with only 40 people. The new matrix may not heal wounds better than standard dressings, and there is a risk of infection or delayed healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MELANOMA SKIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin cancer skin carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WOUND HEAL

Contacts and locations

Locations

Cal Coast Dermatology

Encino, California, 91436, United States
Laser and Skin Surgery Center of Indiana

Indianapolis, Indiana, 46260, United States
Studies in Dermatology

Cypress, Texas, 77429, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.